BioMark: 2025 Achievements & 2026 Vision

About this update from Biomark Diagnostics, Inc.

Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux. Dear BioMark Shareholders and Team, As we reflect on 2025, we celebrate a transformative year that positions BioMark as the leader in early cancer detection and precision diagnostics. What we've accomplished together represents not just scientific breakthroughs—it represents the resilience, dedication, and unwavering commitment of our team to a mission that saves lives. Key Achievements 2025 Team & Capacity Regulatory & Clinical Validation Scientific Leadership & Recognition Strategic Funding & Partnerships What This Means for Our Stakeholders For Our Team You are part of an internationally recognized leader in early cancer detection. Your work directly impacts patient outcomes. Our team expansion reflects confidence in our mission-we hire the best because our science demands excellence. You are changing cancer detection. For Our Shareholders 2026 Catalysts Regulatory & Market Access IP & Competitive Positioning Clinical Data & Publications Commercial Expansion Business Scaling Outreach Revenue & Coverage Our Culture: A Message of Resilience To every member of the BioMark family—from lab scientists to business development, clinical operations, regulatory affairs, and leadership - thank you . This year tested us. We navigated regulatory complexity. We managed ambitious timelines. We scaled operations while maintaining scientific rigor. We faced skepticism and answered with data. And we never backed down. That spirit - that refusal to accept "no" as final, that commitment to excellence even when the path is uncertain—that is BioMark's culture. That is what makes us different. We Are Defined By The investors who backed us, the patients who entrusted us with their samples, the healthcare collaborators who partnered with us - they did so because they saw a team that delivers . In 2026, we will expand that impact. We build upon the achievements of 2025. Together, we will establish BioMark as the global standard in early cancer detection, transform patient outcomes, and do it with the same unwavering commitment that got us here. Our Vision: 2026 and Beyond We have the science. We have the team. We have the partnerships. We have the resolve. The best of BioMark is not behind us. It's ahead of us. Thank you for your trust, your hard work, and your belief in what we're building. Let's finish 2025 strong and make 2026 unforgettable. With deep gratitude and unwavering commitment, BioMark Leadership Team "Science. Resilience. Impact." About BioMark Diagnostics Inc. BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology. Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/ . For further information on BioMark, please contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-370-0779 Email: [email protected] Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws. The CSE has not reviewed, approved, or disapproved of the content of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279263

View stock analysis, news, and events for Biomark Diagnostics, Inc.